TY - JOUR
T1 - Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma
AU - Zinzani, Pier Luigi
AU - Musuraca, Gerardo
AU - Alinari, Lapo
AU - Fanti, Stefano
AU - Tani, Monica
AU - Stefoni, Vittorio
AU - Marchi, Enrica
AU - Fina, Mariapaola
AU - Pellegrini, Cinzia
AU - Castellucci, Paolo
AU - Farsad, Mohsen
AU - Baccarani, Michele
PY - 2007/1
Y1 - 2007/1
N2 - Purpose: The purpose of this study was to evaluate the reliability of positron emission tomography (PET) in patients with follicular lymphoma (FL) after induction treatment. Patients and Methods: In all, 45 previously untreated patients with FL were studied with PET and computed tomography (CT) scans after chemotherapy induction treatment (fludarabine-containing regimens and CHOP [cyclophosphamide/doxorubicin/vincristine/prednisone] chemotherapy). Histopathologic analysis was performed when considered necessary. Results: After treatment, 4 of 5 patients (80%) who had CT-negative/PET-positive findings experienced relapse/progression, compared with only 1 of 22 patients (4.5%) in the CT-negative/PET-negative subset. Among the 18 patients with CT-positive findings, all 6 patients (100%) who had PET-positive findings experienced relapse or progression, compared with 1 of 12 patients (8.3%) who had PET-negative findings. The 2-year progression-free survival rates were 20% and 90% in the CT-negative/PET-positive and CT-positive/PET-negative subsets, respectively (P = 0.0031). During the follow-up, 2 patients, who presented a PET positivity with a negative CT scan, underwent a lymph node biopsy, which confirmed the presence of FL infiltration. Conclusion: In patients with FL, persisting PET positivity is predictive of early disease progression, because it is still highly likely that patients with PET-negative findings will ultimately progress, but this has not yet been manifested during the period of observation.
AB - Purpose: The purpose of this study was to evaluate the reliability of positron emission tomography (PET) in patients with follicular lymphoma (FL) after induction treatment. Patients and Methods: In all, 45 previously untreated patients with FL were studied with PET and computed tomography (CT) scans after chemotherapy induction treatment (fludarabine-containing regimens and CHOP [cyclophosphamide/doxorubicin/vincristine/prednisone] chemotherapy). Histopathologic analysis was performed when considered necessary. Results: After treatment, 4 of 5 patients (80%) who had CT-negative/PET-positive findings experienced relapse/progression, compared with only 1 of 22 patients (4.5%) in the CT-negative/PET-negative subset. Among the 18 patients with CT-positive findings, all 6 patients (100%) who had PET-positive findings experienced relapse or progression, compared with 1 of 12 patients (8.3%) who had PET-negative findings. The 2-year progression-free survival rates were 20% and 90% in the CT-negative/PET-positive and CT-positive/PET-negative subsets, respectively (P = 0.0031). During the follow-up, 2 patients, who presented a PET positivity with a negative CT scan, underwent a lymph node biopsy, which confirmed the presence of FL infiltration. Conclusion: In patients with FL, persisting PET positivity is predictive of early disease progression, because it is still highly likely that patients with PET-negative findings will ultimately progress, but this has not yet been manifested during the period of observation.
KW - Follow-up
KW - Relapse
KW - Restaging
UR - http://www.scopus.com/inward/record.url?scp=33947115428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947115428&partnerID=8YFLogxK
U2 - 10.3816/CLM.2007.n.005
DO - 10.3816/CLM.2007.n.005
M3 - Article
C2 - 17324337
AN - SCOPUS:33947115428
VL - 7
SP - 291
EP - 295
JO - Clinical Lymphoma and Myeloma
JF - Clinical Lymphoma and Myeloma
SN - 1557-9190
IS - 4
ER -